Oncolinx

Oncolinx, in conjunction with the National Cancer Institute is developing the next generation of targeted cancer therapies: antibody-drug conjugates (ADCs). Oncolinx ADCs carry a patented, immune-activating drug payload called the Azonafide directly, and exclusively, to cancer cells, and not healthy cells, thereby avoiding many of the adverse side-effects of chemotherapy.

The Oncolinx platform is partnered with more than 14 leading pharmaceutical companies and 6 academic labs all over the world— concurrently developing ADCs across 30 different cancer indications. Oncolinx aims to enter clinical trials with a partnered program in mid-2017.